Valeant Recalls Nifedipine Extended-Release Tablets Due to Dissolution Failures
Valeant Pharmaceuticals is recalling Nifedipine Extended-Release Tablets, 90 mg, because some lots failed dissolution specifications.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: The recall is classified as FDA Class II, which is reasonably likely to cause temporary or medically reversible adverse health consequences. The hazard is a quality control failure (dissolution) rather than a direct contamination or structural defect causing immediate severe injury.
Plain-English summary
Valeant Pharmaceuticals North America LLC is recalling Nifedipine Extended-Release Tablets, USP, 90 mg, 100 Tablet Bottles. The recall affects 93,237 bottles distributed nationwide in the United States. The product is manufactured for Teva Pharmaceuticals USA and manufactured in Canada by Valeant Pharmaceuticals International, Inc.
The recall was initiated because high out-of-specification dissolution results were found at the 1-hour time point. This means the tablets may not dissolve at the rate required by the United States Pharmacopeia (USP) standards.
Consumers with these specific lot numbers should contact their healthcare provider or pharmacist for guidance. The affected lots include 1309T27, 1309T28, 1311T33, 1311T34, 1312T40, 1312T41, 1403T23, 1403T21, 1405T21, and 1405T22, with expiration dates ranging from August 2015 to April 2016.
The recalled product
- Product
- Nifedipine Extended-Release Tablets, USP, 90 mg, 100 Tablet Bottles, Rx Only. Manufactured for: Teva Pharmaceuticals USA Sailorsville, PA 13960. Manufactured in Canada By: Valeant Pharmaceuticals International, Inc. Steinbach, MB R5G 127 Canada. NDC: 0093-2059-01.
- Manufacturer
- Valeant Pharmaceuticals North America LLC
- Category
- Drug — Prescription Medication
- Hazard
- Affected units
- 93,237
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (16)
- Lot #: 1309T27
- Expiry: 8/15
- Lot #: 1309T28
- Lot #: 1311T33
- Expiry: 10/15
- Lot #: 1311T34
- Lot #: 1312T40
- Expiry: 11/15
- Lot #: 1312T41
- Lot #: 1403T23
- Expiry: 02/16
- Lot #: 1403T21
- Lot #: 1405T21
- Expiry: 04/16
- Lot #:1405T22
- Expiry: 04/16.
Distribution
Distributed nationwide across the United States.
Related recalls
Same manufacturer · Valeant Pharmaceuticals North America LLC
See all →- ModerateValeant Recalls Cardizem CD Capsules for Dissolution Failures
FDA (Drugs) · 2019-02-20
- ModerateValeant Recalls Cardizem CD Capsules for Dissolution Failures
FDA (Drugs) · 2019-02-20
- LowValeant Recalls Diltiazem HCl Capsules for Dissolution Failures
FDA (Drugs) · 2019-02-20
- ModerateValeant Recalls Cardizem CD Capsules for Dissolution Failures
FDA (Drugs) · 2019-02-20
- ModerateValeant Recalls Cardizem CD Capsules for Dissolution Failures
FDA (Drugs) · 2019-02-20
Same hazard · dissolution failure
See all →- ModerateApotex Recalls Paxil Tablets for Failed Dissolution and Stability Testing
FDA (Drugs) · 2026-09-02
- ModerateMylan Recalls Acamprosate Calcium Tablets Due to Dissolution Failure
FDA (Drugs) · 2026-08-26
- ModerateChlorthalidone 25mg tablets failed dissolution specifications in two batches
FDA (Drugs) · 2026-06-24
- ModerateNiacin extended-release tablets failed dissolution testing at 24 hours
FDA (Drugs) · 2026-06-17
- ModerateMinocycline extended-release tablets failed dissolution testing during stability analysis
FDA (Drugs) · 2026-06-17